nivolumab,ipilimumab
bms
['rectal', 'colorectal', 'ipi +', 'nivo', ' ipi ', 'niche-2']
what a thrill! neoadjuvant io (1 dose ipi + 2 doses nivo) in non-metastatic dmmr colorectal cancer (niche-2). major pr in 95% of pts, 67% pcr. look at that waterfall plot! #esmo2022 #paris 
28. MD. PhD student. Medical Oncology trainee at Ramón y Cajal University Hospital (Madrid). ???? ????????? Avid traveller! ????